Ataluren for the treatment of cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 10, Issue 4, 2016, Pages 387-391

  Shoseyov, David ^a   Cohen Cymberknoh, Malena ^a   Wilschanski, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Ataluren; Cystic fibrosis; Ivacaftor; Molecular consequences of class of mutation; Premature termination codons; Therapy directed at the basic defect

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; TOBRAMYCIN;

ALLELE; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG FUNCTION; NONHUMAN; NOSE MUCOSA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; STOP CODON;

EID: 84959042114     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2016.1150181     Document Type: Article

References (34)

1. Rowe SM, Miller S. Sorscher EJ cystic fibrosis. N Engl J Med. 2005;352:1992-2001.
2. Welch EM, Barton ER, Zhuo J, et al., PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87-91.
3. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008;105:2064-2069.
4. Linde L, Kerem B, Nonsense-mediated mRNA decay and cystic fibrosis. Methods Mol Biol. 2011;741:137-154.
5. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations ñ correlation with incidence data and application to screening. Hum Mutat. 2002;19 (6):575-606.
6. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test. 1997;1(1):35-39.
7. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50(1):222-228.
8. De Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60 (7):558-563.
9. CF Foundation. Patients registry 2012. Available from: http://www.cysticfibrosisdata.org/ReportsUS.html file:///C:/Documents%20and%20Settings/shoseyov/My%20Documents/Downloads/2012-CFFPatient-Registry.pdf
10. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080.
11. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059-1065.
12. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68:809-819.
13. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride analysis with classes of CFTR gene mutations. J Pediatr. 1995;127:705-710.
14. Howard M, Frizzell RA, Bedwell DM, Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2:467-469.
15. Clancy JP, Bebök Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163:1683-1692.
16. Wilschanski M, Yahav Y, Yaacov Y, et al., Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433-1441.
17. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest. 2007;117:683-692.
18. Mort M, Ivanov D, Cooper DN, et al. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008;29:1037-1047.
19. Celik A, Kervestin S, Jacobson A. NMD: at the crossroads between translation termination and ribosome recycling. Biochimie. 2015;114:2-9.
20. Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Biol. 2012;13:700-712.
21. Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem. 2010;18:3735-3746.
22. Xue X, Mutyam V, Tang L, et al., Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol. 2014;50:805-816.
23. Lentini L, Melfi R, Di Leonardo A, et al. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol Pharm. 2014;11(3):653-664.
24. McElroy SP, Nomura T, Torrie LS, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol. 2013;11: e1001593.
25. Bidou L, Allamand V, Rousset JP, et al. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med. 2012;18:679-688.
26. Gonzalez-Hilarion S, Beghyn T, Jia J, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012;31:58.
27. Ryan NJ. Ataluren: first global approval. Drugs. 2014;74:1709-1714.
28. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47:430-444.
29. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;15 (182):1262-1272.
30. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;30:719-727.
31. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38:59-69.
32. Kerem E, Konstan MW, De Boeck K, et al. cystic fibrosis ataluren study group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2:539-547.
33. Kotha K, Clancy JP. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Ther Adv Respir Dis. 2013;7:288-296.
34. Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev. 2013;22:66-71.